Educational Notice
Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Injury Recovery & Tissue Repair
This is the cluster where peptide research has generated some of its most compelling preclinical data—and where the gap between animal models and human clinical outcomes is most consequential. BPC-157 and TB-500 are the most discussed compounds in self-experimentation communities for injury recovery, with an extensive and broadly consistent preclinical literature behind them. Neither has completed a Phase I/II/III clinical trial for any injury or tissue repair indication.
The compounds here operate through distinct but often complementary mechanisms: immune modulation and T-cell activity (Thymosin Alpha-1), angiogenesis and connective tissue repair (BPC-157), actin-driven cell migration (TB-500), collagen synthesis and matrix remodeling (GHK-Cu), and anti-inflammatory signaling at injury sites (KPV, LL-37, VIP). Understanding what each compound does—and does not do—is the prerequisite for evaluating the stacking logic that dominates community discussion of this cluster.
Cluster at a Glance
8
Compounds
1
Approved drug (international)
0
FDA-approved
2
Clinical trials data
1
Pilot / limited human data
4
Preclinical or It’s Complicated
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical / It’s Complicated
WADA Prohibited
Compounds in This Cluster
All 8 compounds in the Injury Recovery & Tissue Repair cluster, sorted alphabetically. Evidence tier and WADA status shown on each card.
WADA
BPC-157: What the Research Says about This Pentadecapeptide
Gastric pentadecapeptide studied for tissue repair, tendon healing, and gut protection. Pilot human data only; WADA prohibited.
Read the research →
Copper Peptides for Hair: GHK-Cu vs AHK-Cu
GHK-Cu and AHK-Cu—copper-binding tripeptides with distinct mechanisms. GHK-Cu has topical human data from wound healing and skin contexts; hair-specific clinical evidence is limited to cosmetic-use observations.
Read the research →
GHK-Cu: What the Research Says about the Copper Peptide
Copper-binding tripeptide studied for wound healing, collagen synthesis, and skin remodeling. Evidence varies significantly by route of administration.
Read the research →
KPV (Lysine-Proline-Valine): Research Overview
C-terminal alpha-MSH tripeptide studied for anti-inflammatory effects in gut and wound models. Preclinical evidence only.
Read the research →
LL-37 (Cathelicidin): What the Research Shows
The only human cathelicidin, studied for antimicrobial activity and wound healing. Preclinical evidence only.
Read the research →
WADA
TB-500: What the Research Says about Thymosin Beta-4’s Synthetic Fragment
Synthetic Thymosin Beta-4 fragment studied for tissue repair and cell migration. Preclinical evidence only; WADA prohibited.
Read the research →
Thymosin Alpha-1 (Thymalfasin/Zadaxin): What the Research Shows
Endogenous thymic peptide approved in 35+ countries for hepatitis and immune modulation. Not FDA-approved in the US.
Read the research →
WADA
Thymosin Beta-4: What the Research Shows
Endogenous 43-amino acid actin-sequestering peptide studied for wound healing, cardiac repair (RGN-352 Phase II), and corneal regeneration (RGN-259). TB-500 is its synthetic fragment — distinct compounds.
Read the research →
VIP (Vasoactive Intestinal Peptide): What the Research Shows
Endogenous neuropeptide studied for anti-inflammatory, vasodilatory, and immune-modulatory effects. Phase II human data available.
Read the research →
How These Compounds Relate
The eight compounds in this cluster are not variations on a single mechanism—they address different phases and dimensions of the healing and immune recovery process. Thymosin Alpha-1 is the outlier in the most useful sense: it is the only compound in this cluster with genuine approved-drug status in major international markets, and the only one whose primary mechanism is immunological rather than structural or regenerative. Its place here reflects the immune system’s role in tissue repair—particularly in contexts of chronic infection, surgical recovery, or immune suppression—rather than any direct effect on connective tissue.
BPC-157 works primarily through angiogenesis and growth factor upregulation at the repair site. TB-500 works through actin dynamics and cell migration. GHK-Cu works through collagen and matrix synthesis. KPV, LL-37, and VIP work primarily through anti-inflammatory signaling, reducing the excess inflammation that can delay or impair healing. Thymosin Beta-4 operates through G-actin sequestration—the same core mechanism as TB-500, which is its synthetic fragment—but with a substantially broader biological profile including Phase II cardiac repair and corneal regeneration data.
The community rationale for stacking BPC-157 and TB-500 rests on the idea that their complementary mechanisms—repair signaling and cell migration respectively—should produce additive benefit. This is biologically plausible. It has not been tested in a human clinical trial, and the interaction between these compounds has not been characterized. Stacking them is an extrapolation from individual preclinical profiles, not from stacking-specific data.
GHK-Cu’s position in this cluster requires particular care. Its topical human data—cosmetic and wound care—is real and reasonably well-documented. Its injectable use, which is how it appears in tissue repair stacks, does not inherit that evidence base. The route of administration is not a minor variable.
The TB-500 vs. Tβ4 distinction runs through this entire cluster. Tβ4 (43 amino acids) has Phase II clinical trial data in cardiac repair and corneal wound healing. TB-500 (7 amino acids) does not. They are different molecules with distinct evidence bases. Community sources that use the names interchangeably are eroding an evidence distinction that matters for anyone making a decision about research use.
One naming caution specific to this cluster: Thymosin Alpha-1 and Thymosin Beta-4/TB-500 share the word “thymosin” as a historical artifact of both being isolated from thymus tissue. They are pharmacologically unrelated—different sequences, different mechanisms, different clinical applications. Any source treating them as variations of a single compound is wrong.
The Wolverine Protocol
The most widely documented community stack for injury recovery combines BPC-157 and TB-500, sometimes with GHK-Cu added. This combination is sometimes referred to as the “Wolverine Protocol.” The named protocol guide examines what the stack actually contains, what pharmacological rationale exists for it, and where the evidence runs out.
Named Protocols Explainer
Wolverine, GLOW, and KLOW protocols—what they stack, what the evidence supports, what it doesn’t →
Browse by Condition
Tendon & Ligament Healing
Compounds relevant to connective tissue repair
Muscle Recovery
Compounds relevant to exercise and injury recovery
Wound Healing
Compounds relevant to tissue repair and closure
Related Guides
How to Reconstitute Lyophilized Peptides
Bacteriostatic water, reconstitution ratios, vial handling
Peptide Injection Technique Guide
Subcutaneous and intramuscular injection, site rotation, safety
Peptide Storage and Handling Best Practices
Temperature ranges, freeze-thaw cycles, reconstituted peptide shelf life
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.